Lv2
108 积分 2024-02-29 加入
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
27天前
已完结
Risk of Recurrence in Patients With HER2+ Early-Stage Breast Cancer: Literature Analysis of Patient and Disease Characteristics
1个月前
已完结
Lysosomes as coordinators of cellular catabolism, metabolic signalling and organ physiology
4个月前
已完结
Management of HER2 alterations in non-small cell lung cancer – The past, present, and future
5个月前
已完结
Trastuzumab emtansine for patients with non–small cell lung cancer positive for human epidermal growth factor receptor 2 exon-20 insertion mutations
5个月前
已完结
Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03
5个月前
已完结
Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial
5个月前
已完结
Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial
6个月前
已完结
EP11.02-03 First Line Sintilimab plus Anlotinib vs Platinum-based Chemotherapy in Metastatic NSCLC (SUNRISE): Updated Efficacy and Safety Analysis
8个月前
已完结
Sintilimab plus chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer with disease progression after EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): second interim analysis from a double-blind, randomised, placebo-controlled, phase 3 trial
8个月前
已完结
皖公网安备34019202002308
